<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978198</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0201</org_study_id>
    <nct_id>NCT00978198</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers</brief_title>
  <official_title>ASP1517 Phase 1 Clinical Study - Single and Multiple Oral Dosing of ASP1517 in Healthy Non-elderly Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of ASP1517 after single
      or multiple oral administration in healthy non-elderly adult male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts, single and multiple dose. Within each part participants will
      be randomized to either ASP1517 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ASP1517</measure>
    <time_frame>During 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP1517</measure>
    <time_frame>During 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1517</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>FG-4592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: ≥50.0 kg, &lt;80.0 kg

          -  BMI: ≥18.5 kg/m2, &lt;25.0 kg/m2

          -  Eligible, as judged by the investigator/subinvestigator based on the results of
             physical examinations (subjective symptoms and objective findings) and all tests
             obtained at screening and up to the timing immediately before study medication

          -  Supine blood pressure: Systolic blood pressure ≥90 mmHg, ≤130 mmHg; Diastolic blood
             pressure ≤85 mmHg

          -  Pulse rate at rest in supine position: ≥40 bpm, &lt;100 bpm

        Exclusion Criteria:

          -  Received any investigational drugs in other clinical or post-marketing studies within
             120 days before the screening assessment

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or
             blood components within 14 days before the screening assessment

          -  Received medication within 7 days before hospital admission or is scheduled to receive
             medication

          -  History of drug allergies

          -  Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days
             before the study

          -  Excessive smoking or drinking habit (measure of &quot;excessive&quot;: alcohol: 45 g/day,
             smoking: 20 cigarettes/day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>June 16, 2010</last_update_submitted>
  <last_update_submitted_qc>June 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma , Inc</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety and tolerability</keyword>
  <keyword>Plasma concentration</keyword>
  <keyword>ASP1517</keyword>
  <keyword>FG-4592</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

